The Neurovana Psychiatric Treatment Model
Implement a structured, evidence-based CES care protocol that delivers measurable outcomes and sustainable practice revenue. The device supports the model. The model is the product.
Implement the Neurovana Treatment Model (Not Just Sell Devices)
Cranial Electrotherapy Stimulation (CES) works—but only when delivered as part of a structured clinical program. Neurovana provides the complete implementation framework: protocols, training, billing guidance, and ongoing support. You're not buying devices; you're implementing a proven psychiatric treatment model.
The 7-Visit Protocol (12-Week Clinical Model)
Week 0: Initial Evaluation
Comprehensive psychiatric assessment, patient education, device training, and enrollment in treatment plan. Baseline symptom measurement (GAD-7, PHQ-9, ISI).
Week 1: Loading Phase – Session 2
Assessment of device tolerance, side effect management, adherence troubleshooting. Reinforcement of expectations and daily use protocol.
Week 2: Loading Phase – Session 3
Objective measurement of treatment response using validated scales. Critical checkpoint where many patients feel discouraged — clinical data guides continuation.
Week 3: Loading Phase – Session 4
By this stage, responders show clear benefits. Decision point: continue maintenance, adjust protocol, or discontinue if no objective improvement.
Week 4: Loading Phase – Response Assessment
Comprehensive evaluation of treatment response, objective outcome measurement, decision-making on continuation or discontinuation, and planning for sustained care. This visit is critical for determining long-term treatment strategy and documenting clinical rationale.
Week 8: Optimization
Focus on supporting consistent progress and ensuring the treatment remains comfortable and sustainable for the patient. Adjust treatment intensity or frequency based on patient response and engagement. Address any barriers to continued use to support long-term outcomes.
Week 12: Evaluation & Continuation Planning
Define the long-term treatment strategy based on overall response and patient progress. Transition to maintenance, continue therapy, or discontinue treatment as appropriate, with clear documentation to support clinical decision-making and continuity of care.
Why 7 visits minimum?Why 7 visits minimum? Clinical data shows that Week 12 evaluation is essential for determining long-term effectiveness and planning sustainable care. Revenue projections are based on this 7-visit structure, generating $1,125-$3,800 per patient through billable CPT codes (99205, 99214, 90833). Reimbursement rates vary by payer and provider type.
Clinical Benefits
60-70% response rates when protocol is followed
Higher adherence Higher adherence through structured touchpoints
Objective outcome tracking with validated measures
Ethical stopping criteria when treatment isn't working
Defensible documentation for clinical and billing purposes
Ready to implement this model?
Get the complete protocol, billing codes, and implementation support.
